MX2010009268A - Compuestos que son inhibidores de erk. - Google Patents

Compuestos que son inhibidores de erk.

Info

Publication number
MX2010009268A
MX2010009268A MX2010009268A MX2010009268A MX2010009268A MX 2010009268 A MX2010009268 A MX 2010009268A MX 2010009268 A MX2010009268 A MX 2010009268A MX 2010009268 A MX2010009268 A MX 2010009268A MX 2010009268 A MX2010009268 A MX 2010009268A
Authority
MX
Mexico
Prior art keywords
compounds
erk inhibitors
formula
disclosed
erk
Prior art date
Application number
MX2010009268A
Other languages
English (en)
Spanish (es)
Inventor
Neng-Yang Shih
Hugh Y Zhu
Ronald J Doll
Alan B Cooper
Jagdish A Desai
James J-S Wang
Hon-Chung Tsui
Gerald W Shipps Jr
Yang Nan
Sobhana Babu Boga
Joseph M Kelly
Abdul-Basit Alhassan
Xiaolei Gao
Liang Zhu
Yongqi Deng
Subrahmanyam Gudipati
Mehul F Patel
Sunil Paliwal
Xin Yao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010009268(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010009268A publication Critical patent/MX2010009268A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2010009268A 2008-02-21 2009-02-19 Compuestos que son inhibidores de erk. MX2010009268A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21
PCT/US2009/034447 WO2009105500A1 (en) 2008-02-21 2009-02-19 Compounds that are erk inhibitors

Publications (1)

Publication Number Publication Date
MX2010009268A true MX2010009268A (es) 2010-09-14

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009268A MX2010009268A (es) 2008-02-21 2009-02-19 Compuestos que son inhibidores de erk.

Country Status (23)

Country Link
US (1) US8716483B2 (enExample)
EP (1) EP2260031B1 (enExample)
JP (1) JP5276676B2 (enExample)
KR (1) KR20100117123A (enExample)
CN (1) CN102015693B (enExample)
AR (1) AR070460A1 (enExample)
AU (1) AU2009215534B8 (enExample)
BR (1) BRPI0908120A8 (enExample)
CA (1) CA2714479A1 (enExample)
CL (1) CL2009000394A1 (enExample)
CO (1) CO6300939A2 (enExample)
EC (1) ECSP10010415A (enExample)
ES (1) ES2556353T3 (enExample)
IL (1) IL207530A (enExample)
MX (1) MX2010009268A (enExample)
MY (1) MY152271A (enExample)
NZ (1) NZ587504A (enExample)
PE (1) PE20091491A1 (enExample)
RU (1) RU2525389C2 (enExample)
SG (1) SG188179A1 (enExample)
TW (1) TWI398441B (enExample)
WO (1) WO2009105500A1 (enExample)
ZA (2) ZA201005909B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
EP2316031B1 (en) * 2008-08-19 2016-09-14 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment
WO2011002887A1 (en) 2009-07-02 2011-01-06 Schering Corporation FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
CA2774769A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
EP2584903B1 (en) * 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
BR112013009823A2 (pt) 2010-10-22 2016-07-05 Bayer Ip Gmbh novos compostos heterocíclicos como pesticidas
AU2011329067A1 (en) * 2010-11-16 2013-05-30 Medimmune, Llc Regimens for treatments using anti-IGF antibodies
US9000209B2 (en) 2011-07-22 2015-04-07 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
PE20150666A1 (es) 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
EP2900223B1 (en) * 2012-09-28 2017-10-25 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CA2882950A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US9303043B2 (en) * 2013-03-13 2016-04-05 Greentech, Inc. Process for making benzoxazepin compounds
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
SI3052096T1 (en) 2013-10-03 2018-04-30 Kura Oncology, Inc. EAQ inhibitors and application procedures
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
EP3998258A1 (en) * 2014-12-18 2022-05-18 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl- 1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
MX2017008078A (es) * 2014-12-19 2017-09-28 Merck Sharp & Dohme Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas.
EP3277690B1 (en) 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
US20180250232A1 (en) * 2015-09-03 2018-09-06 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
CN117567338A (zh) 2019-10-09 2024-02-20 拜耳公司 作为农药的新的杂芳基三唑化合物
AU2020394767B2 (en) 2019-12-06 2023-05-25 D3 Bio (Wuxi) Co., Ltd. Spiro compound serving as ERK inhibitor, and application thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
AU3215197A (en) 1996-05-30 1998-01-05 Merck & Co., Inc. A method of treating cancer
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
ES2339196T3 (es) 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
JP4783532B2 (ja) 2000-02-05 2011-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋのインヒビターとして有用なピラゾール組成物
EP1207864A2 (en) 2000-02-05 2002-05-29 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
JP2003527379A (ja) 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60122176T2 (de) 2000-09-15 2007-07-05 Vertex Pharmaceuticals Inc., Cambridge Isoxazole und ihre verwendung als erk-inhibitoren
DE60125980T2 (de) 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
WO2002083648A1 (fr) 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
JP2004538266A (ja) 2001-04-27 2004-12-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド ピラゾール由来のキナーゼインヒビター
JP2004532234A (ja) 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
US6875789B2 (en) 2001-08-03 2005-04-05 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
US6750239B2 (en) 2001-08-03 2004-06-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
EP1438295B1 (en) 2001-10-23 2012-08-15 Merck Serono SA Azole derivatives and pharmaceutical compositions containing them
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
WO2003099212A2 (en) 2002-05-24 2003-12-04 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004026867A2 (en) 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
US7456190B2 (en) 2003-03-13 2008-11-25 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050107386A1 (en) 2003-11-19 2005-05-19 Rama Krishna Narla Methods of treating diseases and disorders by targeting multiple kinases
MXPA06007095A (es) 2003-12-22 2006-09-04 Gilead Sciences Inc Conjugados de fosfonato inhibidores de cinasa.
WO2005100342A1 (en) 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
WO2005100338A1 (en) 2004-04-13 2005-10-27 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators
ES2897422T3 (es) 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
AU2005245877B2 (en) 2004-05-14 2010-06-03 Vertex Pharmaceuticals, Incorporated Prodrugs of pyrrolylpyrimidine ERK protein kinase inhibitors
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
EP1833820A1 (en) 2004-12-23 2007-09-19 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinase and uses therof
CN100377868C (zh) 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ES2372976T3 (es) * 2005-12-13 2012-01-30 Schering Corporation Derivados de indazol policíclicos que son inhibidores de erk.
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
JPWO2007123186A1 (ja) 2006-04-20 2009-09-03 武田薬品工業株式会社 医薬
US7601852B2 (en) 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
WO2008005268A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
US7671832B2 (en) 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
AR068046A1 (es) * 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
MX2009014208A (es) 2007-06-18 2010-01-28 Schering Corp Compuestos heterociclicos y usos de los mismos como inhibidores de erk.
CA2774769A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors

Also Published As

Publication number Publication date
CL2009000394A1 (es) 2011-02-11
CA2714479A1 (en) 2009-08-27
AU2009215534B2 (en) 2014-06-26
EP2260031B1 (en) 2015-10-07
BRPI0908120A8 (pt) 2017-10-24
MY152271A (en) 2014-09-15
TWI398441B (zh) 2013-06-11
PE20091491A1 (es) 2009-09-25
JP5276676B2 (ja) 2013-08-28
ZA201005909B (en) 2014-03-26
US20110189192A1 (en) 2011-08-04
ES2556353T8 (es) 2017-10-13
TW200948799A (en) 2009-12-01
IL207530A (en) 2014-08-31
CO6300939A2 (es) 2011-07-21
NZ587504A (en) 2012-09-28
JP2011513225A (ja) 2011-04-28
ZA201400396B (en) 2014-12-23
CN102015693B (zh) 2014-10-29
AU2009215534A2 (en) 2010-12-23
US8716483B2 (en) 2014-05-06
SG188179A1 (en) 2013-03-28
IL207530A0 (en) 2010-12-30
WO2009105500A1 (en) 2009-08-27
AU2009215534A1 (en) 2009-08-27
EP2260031A1 (en) 2010-12-15
RU2010138635A (ru) 2012-03-27
BRPI0908120A2 (enExample) 2017-08-22
KR20100117123A (ko) 2010-11-02
RU2525389C2 (ru) 2014-08-10
ES2556353T3 (es) 2016-01-15
AR070460A1 (es) 2010-04-07
AU2009215534B8 (en) 2014-07-10
ECSP10010415A (es) 2010-09-30
CN102015693A (zh) 2011-04-13
AU2009215534A8 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
MY152271A (en) Novel compounds that are erk inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
MX2009009786A (es) Inhibidores de la via de hedgehog.
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
PH12014501082B1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2014052563A3 (en) Novel compounds that are erk inhibitors
TW200738725A (en) Unsaturated mTOR inhibitors
MY180812A (en) 4'-o-substituted isoindoline derivattives and compositions comprising and methods of using the same
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
PH12019501639B1 (en) Jak1 selective inhibitors
MX2009014208A (es) Compuestos heterociclicos y usos de los mismos como inhibidores de erk.
PH12014500599B1 (en) Protein kinase inhibitors
MY148609A (en) Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
MX2009005795A (es) Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona.
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
PH12022551241A1 (en) Egfr inhibitors
WO2012058127A3 (en) Novel compounds that are erk inhibitors
MX347928B (es) Derivados de fenetilsulfona isoindolina y su uso.
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
AU2016363719A8 (en) 1,3,4-thiadiazole compounds and their use in treating cancer

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: MICROSOFT TECHNOLOGY LICENSING, LLC

FG Grant or registration